Related Experiment Video
Updated: Aug 16, 2026
06:21
Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
Published on: May 10, 2024
Adjuvant therapy in gastric cancer
Lionel Lim1, Michael Michael, G Bruce Mann
1Peter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia.
Summary
Adjuvant therapy for gastric cancer shows promise, with postoperative chemoradiotherapy improving survival. Ongoing research aims to optimize treatments and identify patients who benefit most from these gastric cancer therapies.
Area of Science:
- Oncology
- Surgical Oncology
- Gastroenterology
Background:
- Gastric cancer presents a poor prognosis with high relapse rates post-surgery.
- Adjuvant therapy's role in improving survival after gastric cancer surgery has been debated due to inconsistent trial results.
- The Gastrointestinal Cancer Intergroup Trial INT 0116 established postoperative chemoradiotherapy as a standard of care, despite ongoing controversies.
Purpose of the Study:
- To review the current landscape of adjuvant treatment for gastric cancer.
- To discuss research directions for optimizing treatment efficacy and delivery.
- To address patient selection for adjuvant therapy in gastric cancer.
Main Methods:
- Review of existing literature and clinical trial data on adjuvant therapy for gastric cancer.
- Analysis of the impact of postoperative chemoradiotherapy.
- Discussion of evolving treatment modalities and future research needs.
Main Results:
- Postoperative chemoradiotherapy demonstrated a survival advantage over surgery alone in a major North American trial.
- Despite this, controversies persist regarding optimal surgical techniques, chemotherapy regimens, and radiation planning.
- Identifying patient subgroups likely to benefit from adjuvant therapy remains a critical area.
Conclusions:
- Adjuvant therapy, particularly chemoradiotherapy, has a role in improving outcomes for gastric cancer patients.
- Further research and clinical trials are essential to refine treatment strategies, reduce toxicity, and standardize care.
- Optimizing adjuvant and neoadjuvant approaches requires addressing surgical, chemotherapeutic, and radiotherapeutic advancements.
More Related Videos
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
10:28Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
Related Concept Videos
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...